This article was originally published in The Tan Sheet
Novartis is voluntarily recalling five lots of GenTeal eye gel and two lots of GenTeal gel drops, the firm announces Nov. 16. The recall is a result of concerns regarding product sterility in both products. Novartis found the presence of mold in "a small number of samples" of the eye gel which may cause infection in susceptible people, particularly those with compromised immune systems, the company states. The sterility of the gel drops also was contested due to a risk of potential contamination. Consumers who may have purchased the products should contact Novartis, the company states...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."